The first recipient described the moment plainly: it gave him the ability to do things on his own again. Behind that sentence sits a device the size of a coin, threaded into the brain, translating intention into a cursor on a screen.
Key takeaways
- Neuralink received FDA clearance for its first-in-human PRIME study in 2023 and implanted the first patient in January 2024.
- The N1 implant carries 1,024 electrodes on 64 flexible threads and is placed by a surgical robot.
- As of late 2025, the company had publicly named five recipients across the PRIME and CONVOY studies.
- The device earned separate FDA Breakthrough Device designations for a vision-restoration project called Blindsight in 2024 and a speech-restoration project in 2025.
The first implant
Noland Arbaugh, a 29-year-old with a spinal cord injury, received the first N1 implant in January 2024 as part of the PRIME study (short for Precise Robotically Implanted Brain-Computer Interface), a trial formally registered as NCT05829199. Within days he was moving a cursor, browsing the web, and playing chess and strategy games using only his thoughts. The company calls the capability "Telepathy" (心灵感应). The early demonstrations mattered less for any single task than for showing the system could be used independently, for hours, outside a lab.
How the device works
The N1 is a fully implanted, wireless brain-computer interface (脑机接口). It holds 1,024 electrode sites spread across 64 flexible polymer threads, each thinner than a human hair. A custom surgical robot inserts the threads into the cortex while avoiding surface blood vessels. The sealed implant recharges wirelessly through the scalp, much like a phone on a charging pad, so there is no permanent cable leaving the body. Signals are amplified and digitized by an onboard chip, then sent wirelessly to a decoder. The design is a deliberate departure from older rigid arrays: no cable protruding through the skin, and far more channels than the 96 of the classic Utah Array.
Who has received it
By late 2025, Neuralink had publicly named five recipients. Arbaugh (spinal cord injury, January 2024) was followed by Alex (spinal cord injury, July 2024), Brad (ALS, November 2024), RJ (spinal cord injury, April 2025), and Mike (ALS, February 2025). Alex became the first to enroll in the CONVOY study, which explores using the N1 to control an assistive robotic arm. One participant used the implant to keep working and to design hardware; another to write with his brain. In one company update, participants reported using the Link independently for an average of 6.5 hours per day, a figure that matters because independent use, not lab supervision, is the real test of whether the device helps someone live. These are individual stories, not population statistics, but they show the device being used for daily life rather than only supervised sessions.
The setback and what it taught
The first implant was not flawless. Some of the flexible threads retracted from the cortical tissue, reducing the number of active electrodes. Neuralink responded by updating its decoding algorithm, and the participant's performance ultimately surpassed his initial level. The company also said it would refine surgical technique — managing brain-fluid levels and inserting threads slightly deeper — to limit future retraction. The episode was a reminder that long-term stability of thin implanted electrodes remains an unsolved engineering problem, not a solved one.
Beyond the first study
Neuralink has expanded geographically. A Canadian study, CAN-PRIME, was approved in late 2024, and the company has announced plans for trials in the United Kingdom and the United Arab Emirates. Separately, the U.S. FDA granted Breakthrough Device designations — a program that speeds review of technologies for debilitating conditions, not an approval to sell — for Blindsight, a vision-restoration project aimed at the visual cortex, in September 2024, and for a speech-restoration project in May 2025.
Honest limitations
A Breakthrough Device designation is not market approval; none of these N1 uses is a commercially cleared therapy yet. The published record is largely the company's own updates and media demonstrations rather than peer-reviewed multi-patient efficacy data, so independent confirmation of long-term safety and benefit is still thin. Thread retraction shows the hardware is evolving in the field. And the headline capabilities — gaming, cursor control — are impressive but narrow; restoring speech or vision at scale is a separate, harder problem the designations only begin to address.
What readers can do now
- If you have a spinal cord injury or ALS and want to explore BCI, ask your neurologist about active clinical trials and read the official study pages rather than social-media clips.
- Separate marketing excitement from regulatory status: a "Breakthrough Device" label means faster review, not that a product is approved or available.
- Follow the FDA device database and clinical-trial registries to track what has actually been authorized versus announced.
A trend note
According to Li An, chief scientist at BrainNet (脑机网), the field's center of gravity is shifting from single impressive demos toward proving the same reliability across many users and many months.